Sunday, August 23, 2026
BioNTech cuts 2026 revenue guidance as COVID sales fade
BioNTech reported Q2 2026 revenue of 105.6 million euros, down from 261 million euros a year earlier, and cut its full-year 2026 revenue guidance to 1.6-1.9 billion euros from 2.0-2.3 billion euros, citing softer global COVID-19 vaccine demand and delayed milestone revenue from an out-licensed program. The company posted a 820.8 million euro quarterly net loss but held 16.6 billion euros in cash, and its stock jumped about 23% on August 19 as investors focused on a pipeline of 14 pivotal oncology trials ahead of incoming CEO Guido Oelkers taking over from co-founder Ugur Sahin by February 2027.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email flightatlas.contact@gmail.com and we will fix it.